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Background. Enterovirus 71 (EV71) causes large outbreaks of hand, foot, and mouth disease (HFMD), with
severe neurological complications and cardio-respiratory compromise, but the pathogenesis is poorly understood.
Methods. We measured levels of 30 chemokines and cytokines in serum and cerebrospinal fluid (CSF)
samples from Malaysian children hospitalized with EV71 infection (n = 88), comprising uncomplicated HFMD
(n = 47), meningitis (n = 8), acute flaccid paralysis (n = 1), encephalitis (n = 21), and encephalitis with cardio-
respiratory compromise (n = 11). Four of the latter patients died.
Results. Both pro-inflammatory and anti-inflammatory mediator levels were elevated, with different patterns
of mediator abundance in the CSF and vascular compartments. Serum concentrations of interleukin 1β (IL-1β),
interleukin 1 receptor antagonist (IL-1Ra), and granulocyte colony-stimulating factor (G-CSF) were raised signifi-
cantly in patients who developed cardio-respiratory compromise (P = .013, P = .004, and P < .001, respectively).
Serum IL-1Ra and G-CSF levels were also significantly elevated in patients who died, with a serum G-CSF to
interleukin 5 ratio of >100 at admission being the most accurate prognostic marker for death (P < .001; accuracy,
85.5%; sensitivity, 100%; specificity, 84.7%).
Conclusions. Given that IL-1β has a negative inotropic action on the heart, and that both its natural antago-
nist, IL-1Ra, and G-CSF are being assessed as treatments for acute cardiac impairment, the findings suggest we
have identified functional markers of EV71-related cardiac dysfunction and potential treatment options.
Enterovirus 71 (EV71) is found globally, but since the
mid-1990s, it has become a major public health
problem in the Asia-Pacific region, causing large out-
breaks of hand, foot, and mouth disease (HFMD),
which may be complicated by aseptic meningitis, en-
cephalitis, fulminant cardio-respiratory failure, and
sudden death [1]. Fatal cases are characterized by neu-
rological involvement, with myoclonus, cerebrospinal
fluid (CSF) pleocytosis, brainstem lesions on magnetic
resonance imaging, and cardio-respiratory compromise;
this manifests as poor peripheral perfusion, reduced
cardiac contractility on echocardiography, and pulmo-
nary congestion on chest x-ray radiograph [2].
The mechanisms underlying cardio-respiratory
compromise in EV71 infection remain unclear.
Because it is associated with brainstem encephalitis,
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